Market news
TypeAll
SortNewest
Assets
BNTC
Sep 28Investing.com
BNTC
Sep 24Investing.comBNTC
Sep 15Yahoo FinanceBNTC
Sep 15Investing.comBNTC
Sep 14Investing.comBNTC
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treatedA Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in OctoberAdditional interim clinical study results from the ongoing BB-301 Phase 1b/2a trial have been accepted for late-breaking
Sep 14Yahoo FinanceBNTC
Benitec Biopharma Files $200 Million Shelf Registration
Benitec Biopharma (BNTC) filed a registration statement Monday with the US Securities and Exchange C
Sep 14Yahoo FinanceBNTC
Jul 28Yahoo FinanceBNTC
This is the newest page. Registered accounts read further back.